A Study to Learn About How Well Yearly Updates to the COVID-19 Vaccine Work to Protect People From COVID-19 and How Much Money People Spend on Healthcare for COVID-19

NCT06923137 · tracked via the Priya Life Science USA tracker

Sponsor

Pfizer

Phase

Observational

Started

2025-04-16

Last updated

2025-11-19

Condition(s) studied

COVID-19 SARS-CoV-2 InfectionCOVID-19COVID-19 InfectionCoronavirus Disease 2019 (COVID-19)COVID-19 (Coronavirus Disease 2019)COVID-19 VaccinationCOVID-19 VaccinesSARS-CoV-2 Infection, COVID19SARS-CoV-2 Infection, COVID-19

Investigational drug(s) / intervention(s)

BNT162b2 →

BNT162b2: BNT162b2

Study summary

The purpose of this study is to learn about how well the yearly updates to the COVID-19 vaccine work in adults (age 18 years and above) with a healthy immune system (the body's cells, tissues and organs that work together to protect your body) and in children (age 6 months to 17 years).

This study will use a collection of insurance claims and state vaccine registry data called HealthVerity. All patient names and other identifying information is removed.

This study will include children who:

* Are 6 months of age to 17 years of age
* Are enrolled for at least 6 months in a row in a health insurance plan that provides data to HealthVerity
* Are enrolled for at least 6 months in a row in a prescription drug insurance plan that provides data to HealthVerity
* Live in the same US state for 6 months in a row
* Live in a US state that requires COVID-19 vaccine reporting and provides all vaccine history data to HealthVerity
* Do not have mismatches in sex and/or year of birth between any of the available datasets
* Do not have records of having had COVID-19 and/or any COVID-19 vaccine in the 90 days before the start of the study

This study will include adults who:

* Are 18 years of age and older
* Are enrolled for at least 12 months in a row in a health insurance plan that provides data to HealthVerity
* Are enrolled for at least 12 months in a row in a prescription drug insurance plan that provides data to HealthVerity
* Have lived in the same US state for at least 12 months
* Live in a US state that requires COVID-19 reporting and provides all vaccine history data to HealthVerity
* Do not have mismatches in sex and/or year of birth between any of the available datasets
* Do not have records of having had COVID-19 and/or any COVID-19 vaccine in the 90 days before the start of the study

This study will use the data that has already been collected, and no treatment or vaccine will be given in the study.

People who match the information above will be followed in the HealthVerity database for up to 6 months following the first day that a new COVID-19 vaccine is available. This information will be reviewed to see if any of the following happen:

* they had a COVID-19 vaccine
* they're diagnosed with COVID-19 in a doctor's office
* they visit the emergency department for COVID-19
* they visit urgent care for COVID-19
* they are hospitalized for COVID-19

The experiences of people who received a COVID-19 vaccine will be compared to the experiences of people who did not receive the vaccine. This will help to understand how well the Pfizer-BioNTech COVID-19 vaccine works at stopping COVID-19.

Eligibility

Sex

ALL

Min age

6 Months

Max age

—

Healthy volunteers

The youngest possible age for any person in any aim of the study is 6 months old. For objectives pertaining to adults, this protocol will be conducted among persons who have all of the following: * At least one year of continuous medical enrollment prior to index date in an insurance plan that contributes to the HealthVerity claims database in the United States. Medical claims are used to measure inpatient, outpatient, emergency department and urgent care encounters. A gap of up to 30 days will be allowed. * At least one year of continuous pharmacy enrollment prior to index date in an insurance plan that contributes to the HealthVerity claims database in the United States. Pharmacy claims are used to measure outpatient dispensations of drugs, vaccines, and other biological products. A gap of up to 30 days will be allowed. * At least one year of continuous state residency in a state with mandatory COVID-19 vaccination reporting that contributes the entire state vaccine registry to HealthVerity. * Does not have discrepancies in sex and/or year of birth between any of the available datasets. These are critical covariates in models as they are amongst the most important risk factors for severe disease. * Did not have documented episode of COVID-19 and/or receipt of any COVID-19 vaccine during the 90 days prior to index date. These persons likely have lower risk of vaccination (the study's exposure of interest) as well as temporarily lower risk of COVID-19 (the study's outcome of interest), which would introduce heterogeneity in estimates were they not excluded. For objectives pertaining to pediatrics, this protocol will be conducted among persons who have all of the following: * At least six months of continuous medical enrollment prior to index date in an insurance plan that contributes to the HealthVerity claims database in the United States. Medical claims are used to measure inpatient, outpatient, emergency department and urgent care encounters. A gap of up to 30 days will be allowed. * At least six months of continuous pharmacy enrollment prior to index date in an insurance plan that contributes to the HealthVerity claims database in the United States. Pharmacy claims are used to measure outpatient dispensations of drugs, vaccines, and other biological products. A gap of up to 30 days will be allowed. * At least six months of continuous state residency in a state with mandatory COVID-19 vaccination reporting that contributes the entire state vaccine registry to HealthVerity. * Does not have discrepancies in sex and/or year of birth between any of the available datasets. These are critical covariates in models as they are amongst the most important risk factors for severe disease. * Did not have documented episode of COVID-19 and/or receipt of any COVID-19 vaccine during the 90 days prior to index date. These persons likely have lower risk of vaccination (the study's exposure of interest) as well as temporarily lower risk of COVID-19 (the study's outcome of interest), which would introduce heterogeneity in estimates were they not excluded.

Primary outcome measure(s)

COVID-19 outpatient encounter in adults — 6 months
Outpatient encounter with ICD-10-CM code: U07.1
COVID-19 inpatient encounter in adults — 6 months
Hospitalizations "for COVID-19" defined as those with an inpatient encounter at an acute care facility with ICD-10-CM code U07.1 "COVID-19" that did not have an additional incidental code (for unintentional injury, physical trauma, poisoning, short-stay \[\< 2 days\] childbirth or serious psychiatric admissions), or a U07.1 hospitalization where treatment used solely for COVID-19 (e.g., remdesivir) was identified regardless of accompanying diagnoses. As a sensitivity analysis, the definition will be relaxed to consider any hospitalization with a U07.1 code, without consideration of incidental findings.
COVID-19 emergency department visit in adults — 6 months
Emergency department visit with ICD-10-CM code: U07.1
COVID-19 urgent care encounter in adults — 6 months
An urgent care encounter with ICD-10-CM code: U07.1 "COVID-19"
COVID-19 critical illness in adults — 6 months
ICU admission, mechanical ventilation, and/or inpatient death. If sample size allows, we will evaluate VE against each component separately
Cost associated with healthcare encounter in adults — 6 months
Mean (standard deviation) and median (Q1-Q3) among all non-zero costs for each care setting of interest
Length of inpatient stay in adults — 6 months
Number of days from admission to discharge expressed as mean (standard deviation) and median (Q1-Q3)

Trial sites (1)

Facility	City	Region	Status
Pfizer	New York	New York

More Pfizer trials in the USA

A Study to Learn About How a New Pneumococcal Vaccine Works in Adults Active, not recruiting

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK) Active, not recruiting

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease Recruiting

Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis Active, not recruiting

A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe Asthma Recruiting

Other trials for the same condition

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease Recruiting

A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised Recruiting

Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study Recruiting

A Study to Learn About COVID-19 Antivirals in People With SARS-CoV-2 Infection From 2023-2026 Active, not recruiting

SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06923137 on ClinicalTrials.gov ↗ ← All trials in the USA